Alcoholism: Rehabilitation

Department of Health and Social Care written question – answered at on 22 June 2022.

Alert me about debates like this

Photo of Paul Bristow Paul Bristow Conservative, Peterborough

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including (a) Nalmefene and (b) Naltrexone as part of an alcohol harm reduction strategy.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) recommends nalmefene as an option for reducing alcohol consumption for people with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. NICE also recommends oral naltrexone for harmful drinkers and people with mild dependence who have not responded to psychological interventions alone, and for people with moderate and severe dependence, following successful withdrawal. NICE recommends that these medications should only be prescribed along with psychosocial intervention.

The Office for Health Improvement and Disparities is developing United Kingdom guidelines for the clinical management of harmful drinking and alcohol dependence, which will include guidance on prescribing nalmefene and naltrexone. Publication of these guidelines is expected later this year.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.